C&R Research signs preferred partnership agreement with 라이브스코어 바카라사이트-based CRO Equilab

[by Kang, In Hyo] C&R Research announced on January 12 that it has recently entered into a conditional exclusive partnership agreement with Equilab International (hereafter referred to as Equilab), a leading contract research organization (CRO) in 라이브스코어 바카라사이트, for close collaboration and joint project execution.

Under the terms of the agreement, the two companies will establish a strategic collaboration framework w라이브스코어 바카라사이트h an operational structure comparable to a single integrated organization, prior라이브스코어 바카라사이트izing mutual cooperation in the execution of clinical trials commissioned in both countries.

First, the partnership will focus on jointly establishing an operational foundation to enhance the execution of regulatory approval-oriented clinical trials conducted simultaneously in Korea and 라이브스코어 바카라사이트. As multiple Phase 3 clinical trials are scheduled to be launched in earnest this year, the significance of this collaborative system lies in its early establishment with the explicit objective of improving overall operational quality, including shortening the regulatory approval timelines.

The two companies will closely collaborate across the full spectrum of clinical trial activ라이브스코어 바카라사이트ies, encompassing clinical trial design, regulatory communications, trial s라이브스코어 바카라사이트e operations, and mon라이브스코어 바카라사이트oring. In particular, they intend to extend this collaboration to large-scale Phase 3 clinical trials in key therapeutic areas for chronic diseases, w라이브스코어 바카라사이트h the goal of proactively ensuring stable trial execution. This is expected to improve both patient recru라이브스코어 바카라사이트ment timelines and the overall cost efficiency of clinical trial operations.

Equilab, 라이브스코어 바카라사이트's first and largest CRO, offers clinical trial services and central laboratory analyses that comply with international standards. According to the company, these capabilities have enabled it to establish a high level of credibility and competitiveness in the global clinical research market.

"We are pleased to enter into a partnership with C&R Research. Indonesia represents a market with substantial potential for novel drug development, and both the regulatory environment and the capacity of clinical trial infrastructure have improved markedly in recent years. We anticipate that Equilab's local expertise will support C&R Research, as well as Korean pharmaceutical and biotechnology companies, in successfully conducting multinational clinical trials in Indonesia," remarked Ronal Simanjuntak, CEO of Equilab.

"Leveraging our experience in multinational clinical trials, we aim to maximize synergy with Equilab's local expertise to deliver highly reliable clinical services to our clients,” said Yoon Moon-tae, CEO of C&R Research. “By establishing global quality standards in Indonesia, a key clinical trial hub in Southeast Asia, we intend to further strengthen our overall clinical development competitiveness," he added.